CALHM1 Antibody is affinity chromatography purified via peptide column.
Immunogène
CALHM1 antibody was raised against a 17 amino acid synthetic peptide near the amino terminus of human CALHM1. The immunogen is located within amino acids 60 - 110 of CALHM1.
CALHM1
Reactivité: Humain
WB, IF (cc), IF (p)
Hôte: Lapin
Polyclonal
Alexa Fluor 488
Indications d'application
CALHM1 antibody can be used for detection of CALHM1 by Western blot at 1 - 2 μ,g/mL. Antibody can also be used for immunohistochemistry starting at 5 μ,g/mL. For immunofluorescence start at 20 μ,g/mL.
Antibody validated: Western Blot in rat samples, Immunohistochemistry in rat samples and Immunofluorescence in rat samples. All other applications and species not yet tested.
Restrictions
For Research Use only
Format
Liquid
Concentration
1 mg/mL
Buffer
CALHM1 Antibody is supplied in PBS containing 0.02 % sodium azide.
Agent conservateur
Sodium azide
Précaution d'utilisation
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Stock
-20 °C,4 °C
Stockage commentaire
CALHM1 antibody can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
anticorps FAM26C, anticorps Fam26c, anticorps RGD1564891, anticorps EG546729, anticorps calcium homeostasis modulator 1, anticorps novel protein similar to vertebrate calcium homeostasis modulator protein family, anticorps CALHM1, anticorps LOC557535, anticorps Calhm1
Sujet
CALHM1 Antibody: Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by a massive loss of neurons in several brain regions and by the presence of senile plaques comprised of aggregated amyloid-beta (Abeta) peptides produced by the endoproteolysis of the amyloid precursor protein (APP). The calcium homeostasis modulator 1 (CALHM1) is a recently identified multipass transmembrane glycoprotein that controls cytosolic Ca2+ concentration and Abeta levels. While some studies suggest CALHM1 is significantly associated with risk of AD, other reports suggest there is no link. CALHM1 has been suggested to modulate the Ca2+-dependent proteolytic process of APP through controlling the level of cytosolic Ca2+.